Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 3c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.95 -0.83%
EPS Growth %: -30.4%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -30.4%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.17, $0.03 better than the analyst estimate of $0.14. Revenue for the quarter came in at $67.9 million versus the consensus estimate of $69.75 million.
GUIDANCE:
Vanda expects to achieve the following financial objectives in 2021:
Full Year 2021 Guidance | |
Total revenues | $270 to $300 million |
HETLIOZ® net product sales | $180 to $200 million |
Fanapt® net product sales | $90 to $100 million |
Year-end 2021 Cash | Greater than $400 million |
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
- Morgan Stanley upgrades CDW on stronger AI-driven server demand
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
